Abacus Global Management 3Q26 Earnings Call - ABACUS GLOBAL MANAGEMENT INC

Explicit Guidance:

• Full-year 2026 adjusted net income guidance raised to $104.5–$106.5 million (up from $100–$106 million), representing up to 24% growth over 2025.
• Full-year 2026 adjusted EPS guidance raised to $1.15–$1.07 (up from $1.00–$1.05).
• Q4 2026 adjusted net income guidance of $28–$30 million (up to 30% growth over Q4 2025).
• Q4 2026 adjusted EPS guidance of $0.28–$0.30.
• Q1 2027 securitization expected to close, with target size not specified but anticipated to be in a similar range to the $400 million Q3 deal.
• Annual target of 2–3 securitizations per year starting in 2027, with potential for higher frequency.
• Long-term target of 70% fee-related revenue mix by 2030.
• Dividend increased 10% to $0.22 per share annually; ex-dividend date set for December 1, 2026.
• Share repurchase program: $100 million authorized through May 2028; current buyback strategy targets average purchase prices in the low $8s or sub-$8 range based on ROI/ROE analysis (comparing stock upside to ~26% ROE).

Business-Segment Outlook:

• LifeArk: First signals indicate strong demand; pipeline holds over $500 million in investable assets with 357 inquiries. Average inquiry value ~$7 million; 91% of inquiries are from clients age 50+ (avg age 66).
• Life Solutions: Revenue growth driven by strong sales of life settlement policies (realized gains up $25.8M YoY); commissions up 145.5% and originations up 281.9% YoY.
• Technology Services: Revenue projected to grow as AI-driven underwriting and screening efficiency improve inbound volume.
• Asset Management: Expected shift in revenue mix toward fee-based earnings (funds and securitizations) rather than one-time gains, particularly in 2027–2028.
• Securitization: New distribution channel expected to drive recurring revenue (50–100 bps annual fees on portfolio value) and residual interest (targeting 10s% IRR).
• Policy Turnover: Annualized turnover ran at 3x in Q3; expected to stabilize in the upper end of the 1.5–2x target range in 2027–2028 due to sustained securitization issuance.
• Realized Gains: Average realized gain on policy sales was 24% in Q3; management expects to model conservatively at 20% long-term, though market conditions may support mid-20s.

Market and Competitive Outlook:

• Wealth Transfer: Anticipates $124 trillion in US wealth transfer over the coming decades; LifeArk positioned to capture planning and asset management for this cohort.
• Pricing & Valuation: Two funds sold 27% of portfolios to outside buyers above NAV, providing independent validation of asset marks.
• Capital Efficiency: Securitization allows for "cheaper capital" (investment-grade rated notes placed with insurance companies) and faster capital recycling.
• Distribution: Shifting mix from wholesale institutional sales (one-time gains) to Funds and Securitizations (recurring fees + residuals) to maximize economics per originated policy.
• Competitive Moat: Proprietary 20-year longevity data and HIPAA-compliant medical insights serve as a barrier to entry for individual planning platforms.
• Market Dynamics: Expect volatility or political shifts (e.g., potential estate tax reductions) to potentially increase the volume of insurance policies sold for estate planning, benefiting origination volumes.

Macro / Industry Outlook:

• Economic/Regulatory: No immediate material regulatory headwinds expected regardless of political party control; favorable path anticipated for underlying insurance contracts.
• Interest Rates/Rates: Conservative modeling accounts for interest rate movements; cost of capital advantages from securitizations help maintain margins.
• Asset Correlation: Longevity assets considered less correlated to broader market volatility, expected to attract capital during periods of economic uncertainty.
• Supply Chain: Origination volume expected to grow consistently in 2027–2028, matching capital deployed and securitization capacity.
• Tax/Regulatory Risks: Potential changes to estate tax levels (e.g., reversal of recent increases) could accelerate policy acquisitions.

Strategic Initiatives:

• LifeArk Launch: Platform now live for individual investors via partnerships with Retirable and Manning & Napier; first referral flow observed.
• Partnerships: Retirable (zero account minimum, AI-driven planning) and Manning & Napier ($18B AUM) actively enrolling clients; expected to drive policy sourcing, lead generation, and fund distribution.
• Securitization: Closed $400M deal in September (largest to date, 8x inaugural size); investment-grade notes placed with insurance companies; next deal planned for Q1 2027.
• ABX Longevity Growth and Income Fund: Public interval fund seeing strong RIA interest; flows expected to begin in Q1 2027 alongside platform onboarding.
• Capital Recycling: Securitization proceeds intended to fund new originations, compounding the "flywheel" of turnover and fee generation.
• Capacity Additions: Expansion of servicing platform to cover 3,905 policies ($8B face value) to support scaled securitization and fund distributions.

Risks and Headwinds to Outlook:

• Portfolio Construction Constraints: Securitization timing and size driven by specific policy profiles and diversification requirements (number of lives) rather than pure demand.
• Interest Rate Sensitivity: Conservative modeling assumes 20% realized gains; short-term rate movements could impact the "conservative" assumption if not offset by cost of capital improvements.
• Market Volatility: Political shifts and regulatory changes in Washington D.C. could alter the estate tax landscape or regulatory treatment of long-term care/insurance products.
• Capital Matching: Must balance inventory levels (too much vs. too little) with capital deployment to avoid misalignment with future securitization dates.
• Execution Risk: Continued success of fee-related revenue targets (70% by 2030) depends on consistent execution of fund flows and securitizations.

Management Tone on the Future:

• Confidence Level: Highly confident in momentum, citing "momentum remains strong" and "strong external confirmation" of asset valuation via securitization.
• Strategic Clarity: Emphasizes a clear transition from a "capital intensive" model to a "fee-based, recurring revenue" model with improved capital efficiency.
• Validation: Management views the $400M securitization oversubscription and above-NAV sales as definitive market validation of the business model and asset quality.
• Long-Term View: Repeated references to "compounding value," "long-term value proposition," and the transformative potential of LifeArk in the $124T wealth transfer.
• Guidance Revision: Second upward revision of 2026 guidance signals high confidence in current operational acceleration.

Miscellaneous:

• Valuation Check: Two funds sold 27% of portfolios above NAV, providing a "strong check" on internal mark-to-market values.
• Cash Conversion: Operating cash flow ratio improved to $1.46 generated for every $1 of adjusted EBITDA year-to-date.
• Debt Structure: Current long-term debt balance $366M (excluding non-recourse); senior notes callable Feb 2027; management views refinancing as a strategic option rather than immediate necessity.
• Employee/Staffing: Hiring payroll from acquisitions increased G&A by $1.8M; strategic projects added $5.2M in legal/professional fees.